IXCHIQ Chikungunya vaccine: UK marketing authorisation withdrawn following safety review
Imported from official source
Following advice from the Commission on Human Medicines (CHM), the MHRA has concluded that the benefit-risk balance for the IXCHIQ chikungunya vaccine is no longer considered favourable and the UK marketing authorisation has been withdrawn.
This version
- Version
- 1 of 1
- Recorded
- October 20, 2026 10:01
- Change
- Initial
- Content hash
d5ed3001986d893923e5dfad5917080c- All versions
- Revision history